Stocks · News reference
ACCC Subjects Zoetis' Acquisition Of Neogen Genomics Business To Phase 2 Review Over Competition Concerns
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 17, 2026, 7:17 AM
- Checked
- Jul 17, 2026, 7:17 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Reported Earlier, Australia Full Employment Change For July 16.3K Vs. 48.9K (Revised) Prior
Read original at benzingaReported Earlier, Australia Employment Change For July -15.8K Vs. 11.7K Est.; 80.2K (Revised) Prior
Read original at benzingaReported Earlier, Australia Wage Price Index (QoQ) For Q2 0.8% Vs. 0.8% Est.; 0.8% Prior
Read original at benzingaGlobal Veterinary Medical Devices Market to Reach $9.1 Billion by 2030, Driven by Rising Pet Ownership and Technological Innovation in Animal Healthcare
The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.
Read original at globenewswire-incTD Cowen Maintains Buy on Zoetis, Lowers Price Target to $94
TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $104 to $94.
Read original at benzinga